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Objective. Our objective was to characterize the demographic information, clinical features, and laboratory data of patients with 
dermatitis herpetiformis (DH). Methods. In this multicentre cross-sectional study, consecutive patients with a new diagnosis of 
DH that referred to nine different Italian centers between 2011 and 2016 were characterized assessing demographic, clinical and 
laboratory findings, and evaluating gender and age differences across selected variables. Results. A total of 151 patients were included. 
Among them, 81 (53.6%) were males and 70 (46.4%) were females, with a male to female ratio of 1.2 : 1. e median age at the time 
of diagnosis was 41 years (range 0–85). Males had a significant longer diagnostic delay if compared to females (9 vs. 3 months, 
respectively; 푝 = 0.01). Direct immunofluorescence was positive in 94.7% of the patients, while duodenal biopsy showed partial 
to total villous atrophy in 70.1% of patients. All the females resulted positive to at least one of the antibodies tested, while a total 
of 12 male patients (10.5%) tested negative to celiac-specific antibodies. Female patients had a high rate (14.1%) of autoimmune 
thyroiditis. Conclusions. Our study confirmed some of the most relevant data regarding DH that have been previously reported 
in the literature. In addition, we found a reduced diagnostic delay in females with respect to males, possibly related to the higher 
sensitivity of serologic testing in females with DH compared to males. Finally, we demonstrated that intestinal involvement could 
be severe in patients with DH and that females should be tested for thyroiditis.
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1. Introduction
Dermatitis herpetiformis (DH) is a chronic inflammatory skin 
disease that is considered the specific cutaneous manifestation 
of celiac disease (CD) [1]. However, only a minority of celiac 
patients develop DH. Moreover, while the prevalence of CD 
in the population is about 1-2% with increasing incidence, 
recent studies demonstrated a reduction of the incidence of 
DH in the last decades, with figures of less than 3-4 cases per 
100 000 inhabitants, making DH a rare disease [2].
DH has a polymorphic clinical presentation, showing ery-
thema, papules, wheals, vesicles, pustules, or blisters oen in 
typical sites, like the elbows, knees, and sacral areas but also 
in a typical sites, such as the folds, the palmo-plantar regions, 
and the scalp, which in some cases may represent the only 
affected sites [3]. Itch is usually very severe, and the patients 
may present with scratching lesions alone.
Histopathology of the skin may show some typical signs 
but is usually unspecific; by contrast, the gold standard for the 
diagnosis is the finding of granular immunoglobulin (Ig) A 
deposits at the dermal papillae or along the dermal–epidermal 
junction by direct immunofluorescence (DIF) of perilesional 
skin, that is not always available and may provide false-nega-
tive results [4].
Due to its rarity, its clinical heterogeneity, the low speci-
ficity of histopathology and the methodological issues of DIF, 
the diagnosis of DH is oen difficult, with a delay in the intro-
duction of GFD [5]. As a consequence, a better knowledge of 
the disease is paramount in order to improve the management 
of the patients, considering that DH is not only a mere skin 
disease but can be associated with all the complications and 
risks related to CD [6].
erefore, we performed a multicenter epidemiological 
study on DH conducted at several dermatologic outpatient 
clinics in Italy, with the aim to characterize the demographic 
information, the clinical features, and the laboratory data of 
the patients.
2. Methods
is was a multicenter cross-sectional study investigating con-
secutive patients with a new diagnosis of DH that referred to 
the Units of Florence, Milan, Padua, Trieste, Genoa, Prato, 
Turin, Catania, and Pavia between 2011 and 2016. e study 
was conducted according to the statements of the Declaration 
of Helsinki and was approved by the institutional review board 
of each hospital involved in the study; all the patients provided 
written informed consent.
Demographic, clinical, and laboratory findings were col-
lected from each patient. Among them, data on the morphol-
ogy and distribution of the skin lesions, on the intensity of 
pruritus using a visual analogue scale (VAS) ranging from 1 
to 10, on specific serology (EMA, anti-tTG, antideamydated 
gliadin peptides (DGP); antiepidermal transglutaminase anti-
bodies (eTG), that are considered to have a high sensitivity 
and specificity for DH, were not included in the analysis 
because they were tested only in a minority of patients since 
they are not routinely investigated), as well as on cutaneous 
or systemic associated diseases were reported when 
available.
Moreover, data on immunopathological findings were 
collected at the time of the diagnosis, with patients still on 
normal gluten-containing diet. In particular, duodenum biop-
sies, performed on about half of the patients, were assessed 
for the severity of CD using the Marsh classification modified 
by Oberhuber [7].
Finally, all the findings of DIF were reported, including 
the type, the localization, and the morphology of the immune 
deposits.
2.1. Statistical Analysis. For descriptive purpose continuous 
data were presented as medians with ranges, while categorical 
variables as numbers with percentages. Gender and age 
differences across selected variables were assessed by means 
of Mann–Whitney U test and Pearson’s Χ2 test (or Fisher’s 
exact test where required) for continuous and categorical data, 
respectively. All tests were considered statistically significant 
at 푝-value < 0.05. Analyses were performed with SPSS v.20.0 
(IBM Corp, Armonk, NY, US).
3. Results
3.1. Demographic Data. During the 5-year study period, in the 
9 Dermatology Units participating to the study, a total of 151 
patients were included. Among them, 81 (53.6%) were males 
and 70 (46.4%) were females, with a male to female ratio of 
1.2 : 1. e median age at the time of diagnosis was 41 years 
(range 0–85), with no differences between males and females 
(푝 = 0.68). irty-one patients (21.4%) were under the age of 
18 at the time of diagnosis, while 23 (15.9%) were aged 65 years 
or above, with no differences in the distribution of females and 
males. ere were two peaks in the distribution of age at the 
time of diagnosis, one in the first decade and the other in the 
fourth-to-sixth decades (Figure 1).
e median diagnostic delay in months calculated as the 
difference between the age at diagnosis and the age at which 
the first symptoms and signs of DH occurred as reported by 
the patients was of 6 months (range 0–239); interestingly, 
males had a significant longer diagnostic delay if compared to 
females (9 vs. 3 months, respectively; 푝 = 0.01).
3.2. Clinical Features. e majority of patients had the classical 
clinical features of DH, showing a polymorphic skin eruption 
consisting of erythema, papules, and vesicles, that were 
found in 111 (73.5%), 92 (60.9%), and 98 (64.9%) patients, 
respectively. Only few patients showed wheals (12.6%) or 
bullous lesions (8.6%).
e distribution of the lesions was typical in most of the 
patients, being the elbows the most frequently involved area 
(124 patients, 84.1%). Other commonly involved sites were 
the sacral region (82 patients, 54.3%), the knees (74 patients, 
49%) and the shoulders (40 patients, 26.5%). e face was 
affected in 14.6% of patients, with a predominance in females 
than in males, although without statistical significance (19.7% 
vs. 10.1%, respectively; 푝 = 0.10). Only 3 patients had mucosal 
lesions.
3BioMed Research International
Some clinical differences were found between paediatric 
and elderly patients. In particular, blisters were detected in the 
latter but not in the former (22.7% vs. 0%; 푝 = 0.009); by con-
trast, shoulders were significantly more involved in paediatric 
patients than in patients above the age of 65 (61.3% and 13%, 
respectively; 푝 < 0.001).
e majority of patients had scratching lesions (75.5%) 
and reported pruritus (93.3%), with a median VAS of 6. About 
a third of the patients (29.5%) had severe pruritus with a 
VAS ≥ 8. No correlation was found between VAS and diagnos-
tic delay of the patients.
Interestingly, paediatric patients had significantly less pru-
ritus than the elderly ones (median VAS 4 and 7, respectively; 
푝 = 0.02). Accordingly, patients above the age of 65 showed 
scratching lesions more frequently than those below the age 
of 18 (90.9% and 48.4%, respectively; 푝 = 0.001).
3.3. Direct Immunofluorescence and Histopathological 
Findings. DIF findings were positive in 143 out of 151 patients 
(94.7%), showing the pathognomonic finding of granular IgA 
deposits (Table 1). Moreover, for 120 patients, the description of 
the immune deposits was more accurate and reported the presence 
of other immunoreactants, accordingly, 5.6% of the patients 
showed IgG deposits, 39.1% IgM deposits, and 68% C3 deposits 
at the dermal papillae or along the dermal-epidermal junction in 
a DH-like pattern. By contrast, perivascular IgA deposits in the 
superficial dermis were found only in 8.7% of patients.
A detailed description of histopathological findings was 
available for review in 74 patients. In the majority of cases, 
typical histopathological findings were detected, including the 
presence of subepidermal blistering (75.7%) as well as inflam-
matory infiltration at perivascular areas of the superficial der-
mis (95.6%) and at the dermal papillae (67.6%). Inflammatory 
cells consisted of neutrophils (93.3%); lymphomonocytes 
(91.1%), and eosinophils (85.7%).
Duodenal biopsies were available for 77 patients (Table 2). 
Among them, 6 patients (7.8%) showed a normal mucosa,11 
patients (14.3%) showed a Marsh 1 degree, indicating the pres-
ence of an increased number of intraepithelial lymphocytes, 
6 patients (7.8%) showed a Marsh 2 degree indicating the 
presence of an increased number of intraepithelial lympho-
cytes and of crypt hyperplasia; 54 patients (70.1%) showed a 
Marsh 3 degree, indicating the presence of an increased num-
ber of intraepithelial lymphocytes and of crypt hyperplasia 
together with partial to total villous atrophy. Among the latter, 
15 patients (21.1%) had a Marsh 3a degree, indicating mild 
villous atrophy, 26 (36.6%) had a Marsh 3b degree, indicating 
subtotal villous atrophy, and 13 (18.3%) had a Marsh 3c degree, 
indicating total villous atrophy. No correlation was found 
between the intestinal involvement and diagnostic delay or 
other clinical features of the patients.
3.4. Serologic Findings. Serologic investigation assessing CD-
specific autoantibodies was performed in most of the patients 
(Table 1). None of the patients tested had IgA deficiency. 
Anti-tTG IgA antibodies were proven to be the most sensitive 
serologic markers for DH, being positive in 101 out of 110 
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Figure 1: Histogram of age distribution at the time of diagnosis among patients included in the study.
Table 1:  Direct immunofluorescence results and circulating au-
toantibodies found in patients with dermatitis herpetiformis at the 
time of the diagnosis.
DIF: direct immunofluorescence; tTG: tissue transglutaminase; EMA: en-
domysium antibodies; DGP: deamydated gliadin peptides.∗Pearson’s Χ2 test 
or Fisher’s exact test where required.
Sex
Total 푃-
value∗M F
N % N % N %
DIF
− 4 6.1% 4 6.5% 8 5.3% 1
+ 77 95.1% 66 94.3% 143 94.7%
Anti-tTG 
IgA
− 6 11.3% 2 3.6% 9 8.2% 0.15
+ 47 88.7% 54 96.4% 101 91.8%
EMA IgA
− 9 18.4% 3 7.0% 13 14.0% 0.11
+ 40 81.6% 40 93.0% 80 86.0%
Anti-DGP 
IgG
− 8 24.2% 0 0.0% 8 15.1% 0.02
+ 25 75.8% 20 100.0% 45 84.9%
Anti-DGP 
IgA
− 17 51.5% 8 40.0% 25 47.2% 0.21
+ 16 48.5% 12 60.0% 28 52.8%
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Associated skin diseases were diagnosed in 23 out of 151 
patients with DH (15.2%). Among them, psoriasis (3.3%), 
atopic dermatitis (2.7%) and vitiligo (2%) were the most fre-
quently associated skin diseases (Table 3).
Associated systemic diseases were found in 43 out of 151 
patients with DH (28.5%). Among them, autoimmune thy-
roiditis was the most frequent, and was found in 11 patients 
(7.3%). Interestingly, the prevalence of autoimmune thyroiditis 
was significantly higher in females than in males with DH 
(14.1% vs. 1.3%, respectively; 푝 = 0.003) (Table 3).
4. Discussion
In the present study, we reported the epidemiological, clinical, 
and immunopathological data of an Italian multicenter retro-
spective study on patients with DH. DH is a rare disease with 
an incidence that varies between different geographical areas. 
While it is relatively more common in Northern Europe [2, 8] 
and in the US [9], DH is very rare in almost all the other 
countries, being exceptional in the Far East, although some 
case series of patients with DH were previously reported in 
the literature [10], especially from Japan [11, 12]. In Italy, the 
exact incidence of DH is not known, although it is considered 
a relatively high incidence country [13]. is was confirmed 
by our work, which in a period of 5 years was able to collect 
151 patients with DH, being one of the largest case series stud-
ies on the disease.
While a female prevalence is reported in CD, previous 
studies on DH showed a male to female ratio ranging from 1.1 
to 1.9 [2]. Accordingly, our study confirmed such data, report-
ing a male to female ratio of 1.2 : 1. is may be possibly related 
to the fact that male patients are seronegative for CD more 
frequently than females that in turn may favour the longer 
diagnostic delay in such population, allowing more time for 
DH to develop [2].
Regarding the age at the diagnosis, we confirmed the data 
from previous studies [2, 10, 14, 15] showing a median age of 
41, without differences between males and females. By contrast, 
we found a high number of DH patients under the age of 18 
(21.4%), while in other case series pediatric population repre-
sented only a minor proportion of patients with DH [2]. A pos-
sible explanation for this discrepancy may be represented by the 
recruitment of pediatric patients; some of the Dermatology 
centers involved in this study usually see also pediatric patients 
with DH, increasing the number of patients below the age of 18. 
(91.8%) of the patients. Moreover, 80 out of 93 patients tested 
for EMA antibodies (86%) resulted positive; similar results 
were found for IgG anti-DGP autoantibodies, that resulted 
positive in 45 out of 53 of the patients tested (84.9%), while only 
28 out of 53 patients (52.8%) tested positive for IgA anti-DGP 
autoantibodies. Interestingly, females showed positivity to IgG 
anti-DGP autoantibodies significantly more frequently than 
males (100% and 75.8%, respectively, 푝 = 0.02). In addition, 
all females resulted positive to at least one of the antibodies 
tested, while a total of 12 male patients (10.5%) tested negative 
to all the serologic tests performed (seronegative DH).
3.5. Celiac Disease and Other Associated Diseases. Since DH is 
the specific skin manifestation of CD, all patients with DH are 
concomitantly diagnosed also as having CD and start a GFD. 
However, in our case series, a diagnosis of CD prior that of 
DH was made in 30 patients (19.9%).
Table 3:  Skin and systemic associated diseases found in patients 
with dermatitis herpetiformis.
Skin associated 
diseases No (%)
Systemic associated 
diseases No (%)
Psoriasis 5 (3.3) Autoimmune thy-roiditis 11 (7.3)
Atopic dermatitis 4 (2.7) Arterial hyperten-sion 9 (6.0)
Vitiligo 3 (2.0) Type 2 diabetes mellitus 7 (4.6)
Urticaria 2 (1.3) Osteoporosis 5 (3.3)
Contact eczema 2 (1.3) Allergic rhinocon-junctivitis 3 (2.0)
Rosacea 2 (1.3) Autoimmune gastritis 1 (0.7)
Telogen effluvium 2 (1.3) Crohn’s disease 1 (0.7)
Bullous pemphigoid 1 (0.7) Gastric cancer 1 (0.7)
Pityriasis rosea 
gibert 1 (0.7) Hairy cell leukemia 1 (0.7)
Prurigo nodularis 1 (0.7) Prostatitis 1 (0.7)
Rheumatoid ar-
thritis 1 (0.7)
Beta thalassemia 1 (0.7)
Type 2 diabetes 
mellitus 1 (0.7)
Table 2: Intestinal involvement in patients underwent duodenal biopsy based on the Marsh classification modified by Oberhuber [8].
Sex
Total 푃-value∗M F
 푁 = 33 %  푁 = 38 %  푁 = 71 %
Grade
1 5 15.2% 6 15.8% 11 15.5%
0.81
2 4 12.1% 2 5.3% 6 8.5%
3a 8 24.2% 7 18.4% 15 21.1%
3b 11 33.3% 15 39.5% 26 36.6%
3c 5 15.2% 8 21.1% 13 18.3%∗Fisher’s exact test where required.
5BioMed Research International
series, more than half of the patients had intestinal histopatho-
logical examination; among them, 7.8% showed negative 
results. ese findings are in agreement with previous data 
from literature, where bowel biopsy has been demonstrated 
to provide false- negative results in up to 10% of the patients 
with CD, depending on the number of duodenal specimens 
that are investigated [21]. Moreover, we found that more than 
70% of the patients had histopathological involvement of the 
duodenum with a Marsh 3 degree, while more than 50% of 
the patients had subtotal or total villous atrophy. Although 
recent papers showed a lower incidence of severe villous atro-
phy in patients with DH than in CD, with a reduction in the 
last years [22, 23], our finding is in agreement with previous 
studies from the literature [24].
In general, serological findings in our patients were sim-
ilar to those from other DH case-series reported in the liter-
ature as well as those of CD patients, with anti-tTG antibodies 
being the most sensitive marker for the diagnosis of DH [3]. 
In addition, we found a high positive rate for EMA, which 
was higher than that of anti-DGP antibodies that, in CD, are 
considered more sensitive than EMA [25]. Unfortunately, 
anti-eTG antibodies were investigated only in a minority of 
the patients, since they are not routinely performed by stand-
ard laboratories and, therefore, were excluded from our 
analysis.
An interesting finding of our study was the higher positive 
rate of antibody testing in females. is difference was statis-
tically significant only for IgG anti-DGP antibodies; however, 
none of the female patients in our study were completely 
seronegative, while 10.5% of the male patients did not show 
any CD-specific circulating autoantibody. Previous studies 
showed similar results, with serologic testing being less sen-
sitive for male patients with CD [26]; such a finding might 
explain the higher diagnostic delay in males than in females.
Finally, in our cohort, few patients had associated skin or 
systemic diseases; among them, autoimmune thyroiditis was 
the most frequent and, according to the literature, it was more 
prevalent in females, with a prevalence that was higher than 
that of the Italian general population [27]. erefore, thyroid 
function and autoantibodies should be tested in each female 
patient with DH.
In conclusion, our study confirmed some of the most rel-
evant data regarding DH that were previously reported in the 
literature, investigating a high number of cases from Italy, 
where such data were scarce. In addition, some interesting 
points arise from our study. Females had a reduced diagnostic 
delay with respect to males, possibly related to the higher sen-
sitivity at serologic testing in them. Moreover, at variance with 
previous believes, we demonstrated that intestinal involvement 
could be severe in patients with DH, with even severe villous 
atrophy at the duodenal biopsy. Finally, we recommend 
screening female DH patients for autoimmune thyroiditis.
Data Availability
e data used to support the findings of this study are available 
from the corresponding upon request.
Another explanation might be related to different genetic back-
ground or different exposure to gluten; accordingly, a previous 
study from our group reported a high percentage of pediatric 
patients among those diagnosed with DH [13].
Of note, the median delay between the onset of symptoms 
and the diagnosis was of 6 months and therefore similar to 
that of a large Finnish study (10 months, decreased to 8 
months in the study period 2000–2014) [5] but shorter than 
in other studies, such as in a study from China [10], where 
DH is rarer than in Italy and the median diagnostic delay was 
found to be of 44 months. is may be related to the focus on 
DH of the centers involved in this study, as well as to the aware-
ness on gluten-related disorders in Italy. Interestingly, females 
had a significantly shorter diagnostic delay than males, prob-
ably due to a major attention of the former to their skin symp-
toms and to the higher frequency of seronegative patients in 
the latter. While this finding was confirmed by some studies, 
suggesting that diagnostic delay may explain the higher inci-
dence of DH in males [2], other papers reported a higher 
diagnostic delay in females [5].
From a clinical point of view, our study confirmed what 
were previously known on DH about the morphology of the 
lesions, their distribution and the occurrence of pruritus that 
was moderate to severe in the majority of the patients [16]. 
Itching is one of the major concerns for patients with DH, and 
it is related at least in part to the prominent T helper 2 phe-
notype of the immune response with release of several 
cytokines such as IL-31 [17].
Interestingly, our data showed that elderly patients had 
significantly more severe itching and a higher frequency of 
scratching lesions than pediatric ones. ese results could be 
explained, at least partly, by the higher degree of dryness of 
elderly skin; moreover, a higher frequency of blisters was 
observed in patients above the age of 65 that might reflect a 
more severe inflammatory disease.
Although no statistical differences were found in lesion 
morphology between males and females, the latter showed a 
higher frequency of face involvement, being the only affected 
area in one female patient of our series. In the literature, face 
involvement is not infrequent; however, it has been reported 
as the sole affected site only in four cases [18].
e gold standard for the diagnosis of DH is the presence 
of granular IgA deposits at the papillary tips or along the der-
mal-epidermal junction found by DIF. In our case series, 
94.7% of the patients showed IgA deposits, while the other 
5.3% did not. e latter, however, were diagnosed as having 
DH due to suggestive clinical findings, compatible histopatho-
logical examination, typical serology for CD, bowel biopsy 
positive for CD, and clinical response to a GFD. e percent-
age of DIF-negative cases are is in agreement with previous 
studies, due to the sensitivity of DIF that is less than 100% 
[19]. False-negative results may occur in several instances, 
including the wrong selection of the biopsy site (if performed 
in involved skin) or if the patient is on GFD (that was the case 
of 2 out of our 8 DIF-negative patients).
According to the guidelines for CD [20], a patient receiv-
ing the diagnosis of DH is automatically considered as having 
CD and does not need a bowel biopsy. However, in our case 
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Additional Points
Key Points. Female patients with dermatitis herpetiformis had 
a reduced diagnostic delay with respect to males, possibly 
related to the higher sensitivity of serologic testing in them. 
Intestinal involvement could be severe in patients with der-
matitis herpetiformis, with even severe villous atrophy at the 
duodenal biopsy. Screening for autoimmune thyroiditis is rec-
ommended in female patients with dermatitis herpetiformis.
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